Get the tools used by (smart)2 investors.
SP500 -2.0%DOW -1.7%FTSE 100 -0.1%NIKKEI -1.0%OIL -0.9%GOLD 0.7%
Sign In
WatchlistsIdeasScreenerData ExplorerChartsSaved Work

Total Debt / EBITDA for Insulet Corporation

Join now and get access to the full platform

Search for company or ETF

 

  0 results available. Select is focused ,type to refine list, press Down to open the menu,

PODD: Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform ...

258.75 USD
Price
– USD
Fair Value
–
Upside
160.19 - 289.46
52-week range
Create ChartCreate ModelAdd To Watchlist

Analysis

Fiscal Years
Trailing Twelve Months
Fiscal Halfs
Fiscal Quarters
Daily
Hide this widget

The following section summarizes insights on Insulet Corporation's Total Debt / EBITDA:

Dec 2016Dec 2018Dec 2020Dec 2022Dec 20240.0x40.0x80.0x120.0x
Performance Summary
  • Insulet's latest twelve months total debt / ebitda is 3.6x
  • Insulet's total debt / ebitda for fiscal years ending December 2020 to 2024 averaged 7.2x.
  • Insulet's operated at median total debt / ebitda of 6.8x from fiscal years ending December 2020 to 2024.
  • Looking back at the last 5 years, Insulet's total debt / ebitda peaked in December 2022 at 11.1x.
  • Insulet's total debt / ebitda hit its 5-year low in December 2024 of 3.6x.
  • Insulet's total debt / ebitda decreased in 2020 (9.6x, -13.0%), 2021 (6.8x, -29.1%), 2023 (5.0x, -54.8%), and 2024 (3.6x, -27.7%) and increased in 2022 (11.1x, +62.8%).

How does Insulet's Total Debt / EBITDA benchmark against competitors?

Hide this widget

We've identified the following companies as similar to Insulet Corporation because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.

Insulet Total Debt / EBITDA Benchmarks
NameTickerTotal Debt / EBITDA
Orthopediatrics CorpNASDAQGM:KIDS-9.3x
Tandem Diabetes Care IncNASDAQGM:TNDM-7.0x
Paragon 28 IncNYSE:FNA-5.2x
Precision Optics Corporation IncNASDAQCM:POCI-1.0x
Sight Sciences IncNASDAQGS:SGHT-0.8x
Retractable Technologies IncNYSEAM:RVP-0.1x
HealthcareSECTOR:HLTH.US-0.1x
Neuroone Medical Technologies CorpNASDAQCM:NMTC-0.1x
Milestone ScientificNYSEAM:MLSS0.0x
Edwards Lifesciences CorpNYSE:EW0.4x
Insulet CorporationNASDAQGS:PODD3.6x
Embecta CorpNASDAQGS:EMBC15.3x

Metric Usage: Total Debt / EBITDA

Hide this widget
total_debt_to_ebitda
Slug
number
Datatype
text
Format
current
Default Period
FY, Q, LTM, YTD
Periods Supported
Free
Plan

To view the full list of supported financial metrics please see Complete Metrics Listing.

Similar Metrics

Hide this widget

Metrics similar to Total Debt / EBITDA in the risk category include:

View Full List

Search for metric or datapoint

Total Debt / EBITDA

A ratio that is calculated as Total Debt (including Capital Leases) divided by EBITDA.

Definition of Total Debt / EBITDA

Sector Benchmark Analysis

Sector
Industry Group
Industry
Hide this widget
-13.8x-5.8x2.2x17.2x0200400600800

The chart above depicts the distribution of total debt / ebitda for companies operating in the Healthcare sector in the Developed economic region. Over 2,140 companies were considered in this analysis, and 2,059 had meaningful values. The average total debt / ebitda of companies in the sector is 0.5x with a standard deviation of 3.3x.

Insulet Corporation's Total Debt / EBITDA of 3.6x ranks in the 87.8% percentile for the sector. The following table provides additional summary stats:

Total Debt / EBITDA In The Healthcare Sector
Economic Risk RegionDeveloped
Total Constituents2,145
Included Constituents2,059
Min-14.7x
Max16.6x
Median0.0x
Mean0.5x
Standard Deviation3.3x

You can find companies with similar total debt / ebitda using this stock screener.

All rights reserved. Terms Of Use